Diabetes has bec ome a major global public health problem. The reasons for the fast expansion of this pandemic is partly to be found in urbanisation and a general ac c eptanc e of so c alled "Western Life Style". The patients suffering from this disease are exposed to the risk of very serious c omplic ations. These are, however, avoidable if the patients are given appropriate c are. The disease shortens life expec tanc y by about 1 0 years and even more if the disease has had an early debut. The c onc ept of diabetes c ontains two very different pathologic al entities, diabetes type 1 and diabetes type 2 , both having in c ommon the c hronic elevation of the blood gluc ose c onc entration and the risk of c omplic ations related to the hyperglyc aemia .
T YPE 1 DIABET ES
Type 1 diabetes is the less frequent than Type 2 : about 1 0 % of the total number in the western world. The global prevalenc e is from 0 .2 5 % in Great Britain. This type preferentially affec ts young adults but sometimes also oc c urs in c hildren. There are great regional differenc es in inc idenc e. The annual inc idenc e in Europe, before the age of 1 6 , varies between 4 0 ·2 and 3 ·2 per 1 0 0 0 0 0 inhabitants, with a pronounc ed north-south gradient.
There is a genetic predisposition for this disease and it is signific antly more frequent in subjec ts c arrying the haplotypes HLA DR3 and DR 4 . Subjec ts c arrying HLA Dq b-5 7 ala/val are at risk whereas the HLA Dq b-asp has a protec ting role. The possible benefit of the researc h on these markers has so far not been put to prac tic able use. But, on the other hand, it has been of great interest for epidemiologic al studies. The role of the genetic s in the oc c urrenc e of the disease is sec ondary: as shown by the weak c onc ordanc e for this disease in homozygous twins, < 3 0 %, in c ontrast to the situation for diabetes, type 2 .
Triggering environmental fac tors, are ill understood, but seem to play a dec isive role; e.g. it has been shown that the oc c urrenc e of type 1 diabetes c an be linked to c oxac ki B4 viral infec tion or to the ingestion of c ow's milk before the age of two months. The proposed explanation is that there exists an antigenic kinship between c ertain antigenic c onstituents of the ß -c ell and these infec tious or alimentary agents: between the epitopes of glutamic ac id dec arboxylase ( GAD) , a c onstituent of the ß c ell, and the c oxac ki B4 virus or the islet c ell antigen, ICA 6 9 , and the albumin of c ow's milk. The normal immunologic al rejec tion of suc h uninvited guests, infec tious or alimentary, may in c ertain genetic ally predisposed persons result in a c hronic pathologic al auto-immune reac tion whic h may, several years later, when 9 0 % of the ß -islet tissue is destroyed result in the c linic ally overt phase of the disease.
Clinical manifestations
The patients suffers, apparently unexpec tedly, from an intensive inc rease of the blood gluc ose c onc entration whic h provokes polyuria, thirst, loss of weight followed by ac idosis and c oma. At this stage the diagnosis is evident and a fasting blood gluc ose c onc entration well above 1 1 mmol/L ( 2 g/L) only c onfirms the diagnosis.
The signs of this auto-immune aggression c an be notic ed in the blood at an early stage well before the c linic al phase in the shape of antibodies; anti-islet tissue ( ICA) , antiinsulin ( IIA) , anti-tyrosinephosphatase ( IA2 ) and above all anti-GAD, the earliest detec table antibody ( Fig 1 ) . Further researc h in this field may be of interest in two situations: in disc overing people at risk for developing type 1 diabetes. This would only be of interest if there was a spec ific immunomodulating treatment available, whic h is effec tive and not iatrogenic and c apable of interrupting the auto-immune disease at suc h an early stage that the main part of the ß -islet tissue would be preserved. This means it has to instituted well before the c linic al stage after whic h it is definitely too late. This type of treatment is at present not available. But several c linic al trials are under way ( ant-CD 3 , DIAPEP 2 7 7 ) .
The researc h on these markers has an interest for the individualisation of LADA or slow type 1 diabetes. This type of diabetes presents itself in the beginning as a type 2 diabetes but transforms rapidly, during a few years, into a stage of underproduc tion of insulin and requires an early treatment with this hormone. Among 1 3 6 0 subjec ts partic ipating in the UKPDS and tested at the time of diagnosis, 1 1 ·8 % showed the presenc e of anti-GAD and 7 ·8 % anti-islet c ell with variable c onc entrations 1 .
T he treatment of type 1 diabetes:
In the c linic al phase of the disease the therapeutic strategy is aimed at preventing ac ute metabolic ac c idents like ac idosis and also preventing late-oc c urring c hronic c omplic ations: c omplic ations c onnec ted to the retinal or renal mic roangiopathy or neuropathy. But also nonspec ific c omplic ations, frequently oc c urring in diabetic s, like peripheral mac roangiopathy or c oronary angiopathy. It generally takes about ten years of badly c ontrolled blood gluc ose c onc entration to c reate these c omplic ations. There is, however, a pronounc ed individual variation, whic h in the c ase of at least the nephropathy is probably c onnec ted to genetic fac tors that are still poorly known.
T he lesson learned from the DCCT
The multic entre prospec tive study by the Diabetes Control and Complic ation Trial ( DCCT) 2 published in 1 9 9 3
showed that intensive insulin treatment c ould reduc e the appearanc e of spec ific diabetes c omplic ations or at least slow their evolution. This study was performed on 1 4 4 1 type 1 diabetic patients, half of them not suffering from retinopathy and the other half showing a mild retinopathy. The patients were treated for 1 -1 5 years before they were randomly divided into two groups.
The first group was treated in a c onventional way ( at that time) with one to two injec tions per day, and selfmonitoring of the blood or urine gluc ose c onc entration and with the goal of the absenc e of func tional signs of the disease.
The sec ond group was treated in a more aggressive way with three to four injec tions per day or an external pump ( 4 0 % of the subjec ts at the time of the study) ; at least four blood gluc ose c onc entration c ontrols per day; daily adjustment of the insulin dose; monthly c onsultation with spec ialists; and interac tive telephone c ontac ts. This treatment brought the mean HbA1 c down to less than 7 ·5 % with the goal set at reac hing the normal range ( < 6 ·0 5 %) . The mean HbA1 c of the c onventionally treated patients remained at about 9 %. There was a reduc tion of the adjusted mean risk of developing retinopathy by 7 6 % in the intensively treated patients in the primary prevention group and its progression was reduc ed by 5 4 % in the patients treated in the same way in the sec ondary prevention group. Comparable results were obtained for nephropathy and neuropathy.
The DCCT has in this way c learly shown that the appearanc e of diabetes-spec ific c omplic ations is direc tly c orrelated with the HbA1 c perc entage. This will c onsequently be the key test to follow and adjust the therapy in these patients ( Fig 2) . This study has also shown that there is a pric e to pay for obtaining a normal gluc ose c onc entration; the appearanc e of severe hypoglyc emia is inversely c orrelated to the HbA1 c perc entage ( Fig 3 ) . The use of ultra-rapid insulin analogues ( and soon the slow ana-logues) and the more frequent use of insulin pumps, should, at least in theory, permit the use of intensive therapeutic sc hedules of the type basal bolus with insulin therapy func tionally adapted to food intake. This therapeutic sc hedule ought to make it easier to obtain good glyc aemic c ontrol, i.e. the HbA1 c at less than 7 % and also a lower risk for hypoglyc aemia.
In prac tic e, due to the lac k of c onsensus regarding therapeutic princ iples, and probably also the lac k of human resourc es for educ ation and intensive follow-up of these patients, the situation will stay heterogeneous and not always satisfac tory even in those c ountries that are blessed with a strong public health infrastruc ture. Thus, a rec ent Frenc h survey showed that in Franc e less than 1 /3 of the patients suffering from type 1 diabetes had HbA1 c at less than 7 ·5 % even though 3 6 different insulin sc hedules were utilised and without showing any c orrelation between number of injec tions and HbA1 c .
T YPE 2 DIABET ES
Type 2 diabetes poses radically different problems.
Pathophysiology
Three mec hanisms c ompete in this disease to inc rease the hyperglyc emia: peripheral insulin resistanc e leading to a diminished musc ular gluc ose up-take, an inc reased hepatic gluc ose produc tion whic h is the princ ipal reason for the fasting hyperglyc aemia at the end of the night and, lastly, diminished insulin produc tion. All these anomalies deteriorate progressively with time, resulting in an inc apac ity to withstand the insulin resistanc e and the progressive aggravation of the metabolic disorder. The prec ise origin of these metabolic anomalies is not known. They are c learly "genetic ally programmed": the c onc ordanc e for type 2 diabetes is more than 9 0 % in homozygous twins. The history of this type of diabetes is c learly familial and this is even more evident if the disease affec ted the parents at a young age. The gene, or rather the genes, responsible are not known, ( exc ept perhaps Capsain-1 0 ) . But it is assumed that type 2 diabetes is genetic ally heterogeneous involving a few genes, whic h suggests heterogeneity in the c linic al phenotype. This disease is thought to be provoked by a c ombination of several genetic variants, where none of these alone is suffic ient to produc e the disease. It is very possible that these individual genes are not pathogenic on their own. The genes involved c ould be genes of "energy storage" and type 2 diabetes c ould be induc ed by "thrifty genotypes": genes favourable in an anc estral situation of severe famine and turned unfavourable in a situation of food in surplus and physic al idleness leading to obesity and later diabetes.
Environment factors
There are, however, some fac tors that play a major role in the genesis of the disease: the prevalenc e of type 2 diabetes in the Japanese living in Japan is not higher than 1 % but inc reases to 1 0 % if the same ethnic group moves to Hawaii or to the west c oast of the USA adopting the so c alled "Americ an way of life" with food c ontaining a large intake of gluc ose and lipids and little physic al ac tivity. The same phenomenon is observed with the Chinese living in China ( 1 ·6 %) or living on island of Mauritius ( 1 3 ·1 %) and the same phenomenon has been desc ribed in several analogue situations. The role of these genetic and environment fac tors is well illustrated by the great differenc e in the prevalenc e of the disease in ethnic groups living in the United States, genetic ally different but living under the same c irc umstanc es with over-eating and reduc ed physic al ac tivity ( Fig 4 ) .
An other important environment fac tor is the inc reased life expec tanc y as the prevalenc e of this type of diabetes inc reases with age.
Thus, the fac t that the population is getting older in the "developed c ountries" as well as in many "developing c ountries", the universal urbanisation with a sedentary way of life with little physic al ac tivity and eating foods ric h in lipids and refined sugar c an well explain the alarming global inc rease of the diabetes pandemic . The number of diabetic s was estimated to 1 4 5 millions in the year 2 0 0 0 and is expec ted to surpass 3 0 0 millions in the year 2 0 2 5 . This expansion is found princ ipally in the 4 5 -6 0 year age group in the "developing c ountries" and in the age group > 6 5 in the "developed c ountries" ( Fig 5 ) .
Clinical manifestations of type 2 diabetes
The diagnostic c riteria are given in Fig 6 . The early c linic al pic ture of this disease is rather treac herous as, in c ontrast to type1 diabetes, the inc rease in hyperglyc emia is very slow and the patients c an stay unsymptomatic for several years. If there is no sc reening program for diabetes it may well happen that the diagnosis is not made before the appearanc e of the c ardinal symptoms like ( thirst, polyuria, and loss of weight) and when the fasting blood gluc ose c onc entration is above1 4 mmol/L ( 2 ·5 g/L) . It may well be that the c linic al diagnosis is not made before 1 0 years after the biologic al first appearanc e. In that situation diagnosis is often made at the oc c urrenc e of mic ro-or mac ro vasc ular c omplic ations. In the United Kingdom Prospec tive Diabetes Study ( UKPDS) 5 0 % of the patients had at least one c omplic ation at the time of diagnosis! In order to make the diagnosis as early as possible before the c omplic ations are overt the c hec king, on at two oc c asions, if the fasting plasma gluc ose c onc entration is above 7 · 0 mmol/L is of great importanc e. Unfortunately there is no international c onsensus about the rules for a systematic sc reening proc edure. However, it is c ertain that that subjec ts having a family history of diabetes run a big risk as well as obese people or those having waist/hip ratio > 0 ·8 for women and > 1 for men. The same holds true for women having a history of gestational diabetes. In c ertain ethnic groups this risk is c onsiderable where people just over 6 0 years of age have the same prevalenc e as the aged.
The age when to begin a sc reening proc edure or the frequenc y of sampling is so far not defined.
Subjec ts having a blood gluc ose c onc entration below the threshold defining diabetes ( Fig 6 ) but having a value above the mean or slightly higher are those who run the highest risk of developing diabetes. The DPP 3 study
showed that 3 0 % of the patients having a fasting plasma gluc ose c onc entration of between 5 ·3 and 7 ·0 mmol/L ( 0 ·9 5 and 1 ·2 5 g/L) and between 7 ·8 and 1 1 ·0 mmol/L ( 1 ·4 0 and 1 ·9 9 g/L) after gluc ose load developed diabetes within the next three years. The same study showed that if you c ould detec t these subjec ts through a simple blood sample and modifying their "life style" one c ould reduc e the inc idenc e by 5 8 % during the three year period.
T he treatment of type 2 diabetes, the lesson learned from U KPDS
The UKPDS1 c onsists of 5 0 0 0 patients suffering from a rec ently diagnosed type 2 diabetes. These patients were randomly grouped into two groups. One group treated with rather slac k therapeutic objec tives and the other treated with stric t therapeutic goals.
This study demonstrated two fundamental fac ts that are essential to know about the effec tive treatment of type 2 diabetes.
• A reduc tion of 0 ·9 % of the group mean value for HbA1 c in the stric tly treated group resulted in a 2 1 % reduc tion of retinopathy during a 1 0 year period, a 3 3 % reduc tion of nephropathy and there was evidenc e of 1 6 % reduc tion of c oronary infarc ts. There exists a c orrelation between the appearanc e of mic ro-or mac ro-vasc ular c omplic ations and the period mean HbA1 c value.
• Eac h of the drugs used initially ( insulin, sulfonylurea, or metformin -for the obese) in single drug therapy failed, after a transitory effec tive phase, without one being better than the other in c ontrolling the glyc aemia. This phenomenon was parallel to the diminishing insulin sec retion.
The therapeutic strategy for type 2 diabetes should evidently be a strategy in whic h new therapeutic modes/ agents are added whenever the glyc emic goals are not ac hieved: the first step based on diet and physic al ac tivity, after that Metformin or Sulfonylurea is added, then both together and then perhaps a tri-therapy with asc arbose or thiazolidinedione ( no c onsensus) . As a final step a c hange to insulin and to begin with a mixed treatment with insulin NPH at bed time and then after a few years when this mixed treatment fails one c an use treatment with several injec tions per day and stop of oral anti-diabetic s using therapeutic sc hedules very similar to those used in the treatment of type 1 diabetes ( no c onsensus) .
Glycaemia goals
There exist several rather similar national and international rec ommendations. The Frenc h National Agenc y for Evaluation, ANAES, rec ommends an optimal threshold value for HbA1 c of 6 .5 % ( with a normal range of < 6 %) . This is very ambitious with the aim of eliminating the diabetic c omplic ations. The treatment must be modified if the HbA1 c is above 8 %. In the interval between these two levels, the treatment should be strengthened in ac c ordanc e with the expec ted advantages and disadvantages.
The value of HbA1 c is the dec isive parameter for dec iding the therapeutic c ourse to be taken by the physic ian. This makes it nec essary that the result is c orrec t, reproduc ible and c omparable to other laboratories. Nevertheless the standardisation of this test is not always realised; in Franc e in 1 9 9 9 the inquiry DIABEST made it c lear that there were at least 2 8 different standards, 5 6 % of upper referenc e ranges given were higher than 6 %.
The treatment of type2 diabetes is not based only on the blood gluc ose c onc entration but inc ludes also the ac tive c onsideration of other vasc ular risk fac tors.
• High blood pressure is present in more than 5 0 % of the patients. The UKPD study showed that the ac tive treatment of this c omplic ation gave a better result on morbidity/ mortality in c ardiovasc ular c omplic ations than c orrec tion of the hyperglyc aemia. The therapeutic goals must be stric ter for these patients as c ompared to a non-diabetic population ( running a lower risk of c ardio-vasc ular disease) . A number of very similar rec ommendations have been published. We keep to the ANAES whic h rec ommends the resting blood pressure should be below 1 4 0 /8 0 mmHg.
• Type 2 diabetes is very often assoc iated with dyslipidaemia. The serum LDL c holesterol c onc entration ought to be kept below 1 ·3 0 g/L ( primary prevention) or below 1 ·0 g/L ( sec ondary prevention) by dietary restric tions or if nec essary by drug therapy.
Also the serum triglyc erides , atherogenic in diabetic s, should be kept at below 2 g/L ( primary prevention) or below 1 ·5 g /L ( sec ondary prevention) by dietary restric tion or eventually with the addition of fibrates.
• all this should be c oupled to fighting smoking and sedentary life style.
Paying this pric e it may be possible to avoid the c hronic diabetic c omplic ations. It would be advantageous to perform a very early thorough c hec k up on these patients. It is frequently rec ommended to make this c hec k up annually in the future.
This c hec k up should inc lude the searc h for signs of retinopathy by retinal examination, the nephropathy by determining the 2 4 h mic roalbumin exc retion the serum c reatinine c onc entration and the neuropathy by c linic al examination ( diapason or monofilament) looking for c arotid arteritis or thermo by palpating the pulse and ausc ultation over the arteries and in the c ase anomalies supplemented by a Doppler examination. Disc overing c oronary insuffic ienc y is more problematic , it is often silent in diabetic s and c linic al examination and ECG taken at rest add little. However, c oronary ac c idents are responsible for more than 5 0 % of the inc reased mortality in type 2 diabetes. Physic al exertion tests and pharmac ologic al tests c ould be used in a situation of partic ular risk. Unfortunately, there is no evident c onsensus c onc erning these situations. The risk equations ought to be a useful aid for the definition of patients to be further examined.
CONCLUSION
In type 1 and type 2 diabetes the therapeutic dec isions and the c linic al prognosis rely to a very large extent on laboratory test results. It is of great importanc e for the c linic ian to have a c orrec t and reliable determination of the blood gluc ose c onc entration, and the HbA1 c whic h ought to be standardised, the urine mic roalbumin exc retion rate, the serum c reatinine, the serum LDL c holesterol and the triglyc eride c onc entrations.
Conc erning type 2 diabetes systematic sc reening of the general population or at least of risk groups for fasting blood gluc ose c onc entration would be suitable for making an early diagnosis and permit a real prevention of diabetic c omplic ations.
